|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5244792A
(en)
|
1984-04-06 |
1993-09-14 |
Chiron Corporation |
Expression of recombinant glyoprotein B from herpes simplex virus
|
|
JPH0668B2
(ja)
|
1985-08-30 |
1994-01-05 |
財団法人化学及血清療法研究所 |
単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
GB9415369D0
(en)
|
1994-07-29 |
1994-09-21 |
Lynxvale Ltd |
Mutant virus
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6071742A
(en)
|
1997-03-05 |
2000-06-06 |
Board Of Regents Of The University Of Nebraska |
Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
|
|
WO1998040475A1
(en)
|
1997-03-11 |
1998-09-17 |
Abbott Laboratories |
Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
|
|
EP0970128A1
(en)
|
1997-03-21 |
2000-01-12 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
EP1002119A1
(en)
|
1997-07-31 |
2000-05-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeted hsv vectors
|
|
US6989435B2
(en)
|
1997-09-11 |
2006-01-24 |
Cambridge University Technical Services Ltd. |
Compounds and methods to inhibit or augment an inflammatory response
|
|
WO1999031241A1
(en)
|
1997-12-17 |
1999-06-24 |
Immunex Corporation |
Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
CA2326389C
(en)
|
1998-04-21 |
2007-01-23 |
Micromet Gesellschaft Fur Biomedizinische Forschung Mbh |
Novel cd19xcd3 specific polypeptides and uses thereof
|
|
EP0953639A1
(en)
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
EP1002864A1
(en)
|
1998-11-10 |
2000-05-24 |
Universita' degli studi di Bologna |
HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US6897057B1
(en)
|
1999-08-31 |
2005-05-24 |
The General Hospital Corporation |
Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
AU2001233027A1
(en)
|
2000-01-27 |
2001-08-07 |
Genetics Institute, Llc |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
|
CA2401252A1
(en)
|
2000-03-17 |
2001-09-20 |
Boehringer Ingelheim Pharma Kg |
Human and humanized fap-alpha-specific antibodies
|
|
KR20080023768A
(ko)
|
2000-03-30 |
2008-03-14 |
화이트헤드 인스티튜트 포 바이오메디칼 리서치 |
Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
|
|
CN100523215C
(zh)
|
2000-12-01 |
2009-08-05 |
马普科技促进协会 |
介导rna干涉的小rna分子
|
|
EP1381280B1
(en)
|
2001-03-27 |
2011-05-11 |
Catherex, Inc. |
Viral vectors and their use in therapeutic methods
|
|
JP2005523681A
(ja)
|
2001-10-04 |
2005-08-11 |
イミュネックス・コーポレーション |
Ｕｌ１６結合タンパク質４
|
|
KR100900249B1
(ko)
|
2001-12-07 |
2009-05-29 |
포항공과대학교 산학협력단 |
ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
|
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
US8927251B2
(en)
|
2002-10-07 |
2015-01-06 |
The University Of Chicago |
Targeting of herpes simplex virus to specific receptors
|
|
KR100944575B1
(ko)
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Ｃｄ20에 대한 인간 모노클로날 항체
|
|
US7563869B2
(en)
*
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
US20060240024A1
(en)
|
2003-02-28 |
2006-10-26 |
The Johns Hopkins University |
T cell regulation
|
|
EP1601681A4
(en)
|
2003-03-12 |
2006-11-29 |
Univ Duke |
oligonucleotide mimetics
|
|
US7473418B2
(en)
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
|
KR100845354B1
(ko)
|
2004-03-26 |
2008-07-09 |
화이자 프로덕츠 인코포레이티드 |
항－ｃｔｌａ－4 항체의 용도
|
|
KR101295733B1
(ko)
|
2004-08-20 |
2013-08-13 |
비랄리틱스 리미티드 |
혈액암의 치료방법 및 조성물
|
|
WO2006029219A2
(en)
|
2004-09-08 |
2006-03-16 |
Ohio State University Research Foundation |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
|
WO2006050211A2
(en)
|
2004-10-28 |
2006-05-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
|
|
CN102166218A
(zh)
|
2005-01-17 |
2011-08-31 |
溶瘤病毒有限公司 |
治疗肿瘤的方法和组合物
|
|
DK2002003T3
(en)
|
2005-05-27 |
2016-03-21 |
Ospedale San Raffaele Srl |
Gene vector comprising miRNA
|
|
DK1907000T4
(da)
|
2005-06-08 |
2020-03-30 |
The President And Fellows Of Harvard College |
Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
US8007796B2
(en)
|
2005-12-16 |
2011-08-30 |
Micromet Ag |
Means and methods for the treatment of tumorous diseases
|
|
JP2009521474A
(ja)
|
2005-12-21 |
2009-06-04 |
メディミューン，エルエルシー |
ＥｐｈＡ２ＢｉＴＥ分子およびその使用
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
WO2007123737A2
(en)
|
2006-03-30 |
2007-11-01 |
University Of California |
Methods and compositions for localized secretion of anti-ctla-4 antibodies
|
|
WO2007137328A1
(en)
|
2006-05-26 |
2007-12-06 |
Apollo Life Sciences Limited |
An isolated il-12 molecule or chimeric molecules thereof
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
JP2008066402A
(ja)
|
2006-09-05 |
2008-03-21 |
Fujifilm Corp |
撮像素子および撮像装置
|
|
WO2009016433A2
(en)
*
|
2006-09-15 |
2009-02-05 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
|
EP2125032A4
(en)
|
2007-02-20 |
2011-02-23 |
Mayo Foundation |
CANCER TREATMENT WITH VIRAL NUCLEIC ACID
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
WO2008134878A1
(en)
*
|
2007-05-04 |
2008-11-13 |
University Health Network |
Compositions and methods for cancer treatment
|
|
CA2687301C
(en)
|
2007-05-09 |
2016-08-23 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthetic herpes simplex viruses type-1 for treatment of cancers
|
|
US9416165B2
(en)
|
2007-10-26 |
2016-08-16 |
The Regents Of The University Of California |
Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
|
|
WO2009100140A1
(en)
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
WO2009111892A1
(en)
|
2008-03-14 |
2009-09-17 |
Ottawa Health Research Institute |
Microrna mediated oncolytic targeting
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
NO2700405T3
(enExample)
|
2008-05-29 |
2018-09-01 |
|
|
|
GB0810912D0
(en)
|
2008-06-13 |
2008-07-23 |
Inst Animal Health Ltd |
Vector
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
CA2755245A1
(en)
|
2009-03-13 |
2010-09-16 |
Egen, Inc. |
Compositions and methods for the delivery of biologically active rnas
|
|
ES2385251B1
(es)
*
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
EP3578657B1
(en)
|
2010-04-06 |
2024-03-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
JP5652830B2
(ja)
|
2010-04-09 |
2015-01-14 |
国立大学法人 東京大学 |
マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
|
|
WO2011130749A2
(en)
|
2010-04-16 |
2011-10-20 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
WO2012006181A2
(en)
|
2010-06-29 |
2012-01-12 |
Mount Sinai School Of Medicine |
Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
|
|
PE20171512A1
(es)
|
2010-08-13 |
2017-10-20 |
Roche Glycart Ag |
Anticuerpos anti-fap
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
ES2704632T3
(es)
*
|
2011-09-08 |
2019-03-19 |
Univ New York |
Virus de herpes simplex oncolítico y sus usos terapéuticos
|
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
|
PL3351261T3
(pl)
|
2011-10-11 |
2021-12-06 |
Universität Zürich |
Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
|
|
EP2591796A1
(en)
|
2011-11-10 |
2013-05-15 |
Universität Zürich |
Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
|
|
ES2918580T3
(es)
|
2011-10-17 |
2022-07-19 |
Io Biotech Aps |
Inmunoterapia basada en PD-L1
|
|
US20130156808A1
(en)
|
2011-11-22 |
2013-06-20 |
Stipan Jonjic |
Vaccine comprising beta-herpesvirus
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
US10238698B2
(en)
|
2012-01-25 |
2019-03-26 |
Dnatrix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
US20150250837A1
(en)
*
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014138314A1
(en)
*
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
US20160015749A1
(en)
*
|
2013-03-05 |
2016-01-21 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
EP3461491B1
(en)
|
2013-04-18 |
2024-11-13 |
TILT Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
|
US20160163211A1
(en)
|
2013-05-16 |
2016-06-09 |
Pearson Education, Inc. |
Accessible content publishing engine
|
|
DK3184641T3
(da)
|
2013-10-28 |
2020-08-03 |
Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Onkolytisk hsv-vektor
|
|
AU2015222685A1
(en)
|
2014-02-27 |
2016-09-08 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
DK3552615T3
(da)
*
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
JP6810687B2
(ja)
|
2014-10-08 |
2021-01-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｆａｐ及びｄｒ５に特異的な二重特異性抗体と化学療法剤との併用療法
|
|
WO2016115274A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
JP6954648B2
(ja)
|
2015-10-19 |
2021-10-27 |
シージー オンコロジー， インコーポレイテッド |
併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
|
|
US11155622B2
(en)
*
|
2015-12-17 |
2021-10-26 |
Psioxus Therapeutics Limited |
Virus encoding an anti-TCR-complex antibody or fragment
|
|
EP3400291B2
(en)
|
2016-01-08 |
2024-02-28 |
Replimune Limited |
Engineered virus
|
|
AU2017212713B2
(en)
|
2016-01-27 |
2023-01-19 |
Oncorus, Inc. |
Oncolytic viral vectors and uses thereof
|
|
US11497781B2
(en)
|
2016-03-10 |
2022-11-15 |
Cg Oncology, Inc. |
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
|
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
|
|
CA3032669A1
(en)
|
2016-08-01 |
2018-02-08 |
William Jia |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
|
CN110050062A
(zh)
|
2016-08-09 |
2019-07-23 |
阿尔莫哈纳德·阿尔卡亚尔 |
表达il12的溶瘤弹状病毒
|
|
TW201825511A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現免疫檢查點調節子的溶瘤病毒
|
|
EP3534923A4
(en)
|
2016-11-01 |
2020-05-27 |
DNAtrix, Inc. |
COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS
|
|
US11298420B2
(en)
|
2016-12-21 |
2022-04-12 |
Memgen, Llc |
Armed oncolytic viruses
|
|
WO2018118967A1
(en)
|
2016-12-21 |
2018-06-28 |
Memgen, Llc |
Armed replication-competent oncolytic adenoviruses
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|